MX2011011431A - Composicion para el tratamiento de cancer de prostata. - Google Patents

Composicion para el tratamiento de cancer de prostata.

Info

Publication number
MX2011011431A
MX2011011431A MX2011011431A MX2011011431A MX2011011431A MX 2011011431 A MX2011011431 A MX 2011011431A MX 2011011431 A MX2011011431 A MX 2011011431A MX 2011011431 A MX2011011431 A MX 2011011431A MX 2011011431 A MX2011011431 A MX 2011011431A
Authority
MX
Mexico
Prior art keywords
treatment
composition
prostate cancer
prostate
cancer
Prior art date
Application number
MX2011011431A
Other languages
English (en)
Inventor
Per Cantor
Tine Kold Olesen
Lars Erichsen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2011011431A publication Critical patent/MX2011011431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporciona una composición para el tratamiento del cáncer de próstata.
MX2011011431A 2009-05-01 2010-04-30 Composicion para el tratamiento de cancer de prostata. MX2011011431A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09251242 2009-05-01
US18781909P 2009-06-17 2009-06-17
PCT/IB2010/001063 WO2010125468A1 (en) 2009-05-01 2010-04-30 Composition for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2011011431A true MX2011011431A (es) 2012-02-23

Family

ID=41066059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011431A MX2011011431A (es) 2009-05-01 2010-04-30 Composicion para el tratamiento de cancer de prostata.

Country Status (18)

Country Link
US (1) US8722088B2 (es)
EP (1) EP2424503B1 (es)
JP (5) JP5973909B2 (es)
KR (1) KR101795643B1 (es)
CN (2) CN105663059A (es)
AR (1) AR078224A1 (es)
AU (1) AU2010243273B2 (es)
BR (1) BRPI1010874A8 (es)
CA (1) CA2759888A1 (es)
ES (1) ES2641767T3 (es)
IL (1) IL215772A (es)
MX (1) MX2011011431A (es)
NZ (1) NZ595767A (es)
RU (1) RU2536245C2 (es)
SA (1) SA110310340B1 (es)
TW (2) TWI583391B (es)
WO (1) WO2010125468A1 (es)
ZA (1) ZA201107879B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
HRP20220751T1 (hr) 2010-02-01 2022-09-02 Rebiotix, Inc. Bakterioterapija clostridium difficile kolitisa
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2632934B1 (en) 2010-10-27 2016-11-30 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
TWI580443B (zh) 2012-06-01 2017-05-01 菲瑞茵公司 地蓋瑞利（ｄｅｇａｒｅｌｉｘ）之製備技術
LT3003330T (lt) 2013-06-05 2018-10-25 Rebiotix, Inc. Mikrobiotos atstatymo terapija (mat), kompozicijos ir gamybos būdai
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
TWI571254B (zh) * 2016-01-08 2017-02-21 誠熱實業股份有限公司 放射治療用之醫療輔助裝置
CN105769774A (zh) * 2016-03-02 2016-07-20 张光泉 一种注射用醋酸地加瑞克冻干组合物及其制备方法
US10933134B2 (en) * 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
WO1992019651A1 (en) 1991-04-25 1992-11-12 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP1404384B1 (en) * 2001-07-11 2007-03-21 SCA Hygiene Products AB Coupling of cyclic oligosaccharides to polysaccharides
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
NZ538928A (en) * 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8105292B2 (en) 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2632934B1 (en) 2010-10-27 2016-11-30 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
JP6376975B2 (ja) 2011-07-15 2018-08-22 フェリング ベスローテン フェンノートシャップ ピコスルファート組成物が投与される結腸内視鏡検査の時間調整をする方法

Also Published As

Publication number Publication date
AU2010243273A1 (en) 2011-11-10
CN105663059A (zh) 2016-06-15
JP2020183444A (ja) 2020-11-12
ES2641767T3 (es) 2017-11-13
ZA201107879B (en) 2012-07-25
EP2424503B1 (en) 2017-07-05
JP7296922B2 (ja) 2023-06-23
IL215772A0 (en) 2012-01-31
NZ595767A (en) 2012-12-21
KR20120015310A (ko) 2012-02-21
TWI583391B (zh) 2017-05-21
JP2012525373A (ja) 2012-10-22
TWI508734B (zh) 2015-11-21
JP2015157818A (ja) 2015-09-03
US20100305042A1 (en) 2010-12-02
IL215772A (en) 2016-10-31
AR078224A1 (es) 2011-10-26
EP2424503A1 (en) 2012-03-07
CN102421414A (zh) 2012-04-18
JP6462447B2 (ja) 2019-01-30
TW201600106A (zh) 2016-01-01
TW201039840A (en) 2010-11-16
RU2536245C2 (ru) 2014-12-20
SA110310340B1 (ar) 2015-02-04
WO2010125468A1 (en) 2010-11-04
RU2011142843A (ru) 2013-06-10
BRPI1010874A2 (pt) 2017-05-30
US8722088B2 (en) 2014-05-13
JP2023093643A (ja) 2023-07-04
BRPI1010874A8 (pt) 2018-01-02
CA2759888A1 (en) 2010-11-04
KR101795643B1 (ko) 2017-11-09
JP2022088517A (ja) 2022-06-14
JP7297116B2 (ja) 2023-06-23
AU2010243273B2 (en) 2016-06-16
JP5973909B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
MY160390A (en) Vinyl indazolyl compounds
EP2482849A4 (en) COMBINED IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL218575A0 (en) Treatment of cancer
IL224370B (en) Combined treatment of prostate cancer
HUE043569T2 (hu) Vegyületek rák kezelésére
MX2011006290A (es) Compuestos de aza-azuleno.
MX352926B (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
IN2011KN03851A (es)
MX2014005458A (es) Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
SI2605764T1 (sl) Sestavki za zdravljenje raka
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
HK1254607A1 (zh) 用於治療癌症的有機砷化合物
GB0916686D0 (en) Treatment of cancer
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
JO3550B1 (ar) مركب لمعالجة سرطان البروستاتا
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
AU2009900764A0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration